BioSig Technologies Secures $9M in Equity Financing to Advance Its Electrophysiology Signal Acquisition and Analysis System for Arrhythmia Treatment

VCBeat (WeChat ID: vcbeat) has learned that medical device company BioSig Technologies recently raised $9 million in a new round of equity financing. This round involved 103 unnamed investors.

BioSig Technologies, founded in 2009 and headquartered in Minnesota, USA, is a medical device company. Since its inception, the company has secured 11 rounds of financing. In August 2018, it raised $6 million in equity financing.

BioSig Technologies has developed a system called Pure EP. This system is an electrophysiology (EP) signal acquisition and analysis platform designed for the rapidly expanding electrophysiology market. It is intended to acquire and display high-fidelity cardiac signals for physicians performing catheter ablation procedures, enabling the detection of cells responsible for life-threatening arrhythmias and supporting clinical decision-making.

Arrhythmia is a common cardiac disorder characterized by tachycardia, bradycardia, or irregular heartbeats, and it represents one of the leading causes of mortality among patients with heart disease. Pharmacological therapy and catheter ablation are the primary treatment modalities for arrhythmia. However, pharmacological therapy often lacks efficacy, particularly in patients with advanced-stage heart disease, while catheter ablation is associated with low success rates and high costs.

It is understood that one of the main reasons for the low success rate of catheter ablation procedures is the inability of physicians to distinguish cardiac signals from noise. Numerous devices in the operating room generate significant interference when operating simultaneously, and traditional mapping and recording systems are susceptible to interference from radiofrequency energy, ultrasound, MRI, and CT scans. In contrast to conventional equipment, Pure EP can reduce or eliminate noise and artifacts generated during catheter ablation procedures, enabling physicians to obtain high-fidelity signals as low as 1 microvolt, thereby helping them work more quickly and accurately.

It is reported that BioSig Technologies aims to dominate the $20 billion electrophysiology market. In August 2018, Pure EP received FDA 510(k) clearance and was successfully launched in the United States. In November of the same year, BioSig Technologies entered into an agreement with the Texas Cardiac Arrhythmia Institute at St. David’s Medical Center to conduct human studies using its Pure EP System. Additionally, BioSig Technologies is collaborating with leading experts and organizations in the healthcare industry, such as the Mayo Clinic, to develop electrophysiological signal processing technologies, enabling Pure EP to provide novel therapeutic and diagnostic solutions for neurology and ophthalmology.

(Compiled by Jiao Yanli)